Option chain shows key data for Serve Robotics Inc's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Serve Robotics Inc.

Serve Robotics Inc (OTC:SBOT) Stock, Option Chain

News

Movers & Shakers

Pre-Market Outlook

Markets

Movers

Trading Ideas

General

ADIL

AIHS

ARMP

BLIN

BOOT

BSGM

CAPL

CATO

CONN

COOP

CTHR

DELL

ELTK

FCAU

FTSV

GNCA

HIIQ

HOTH

MNOV

MPAA

MYOV

NOVN

NTNX

OCUL

OKTA

ONVO

OPTT

QTRX

RRGB

SBGL

SBOT

SCHL

SMTX

SPNS

TLRD

TPTX

TRVI

VCYT

VERI

VNRX

VUZI

XBIT

64 Biggest Movers From Friday

Eurozone

Commodities

Global

Intraday Update

STAR

Mid-Afternoon Market Update: Dow Falls Over 300 Points; Williams-Sonoma Shares Climb On Upbeat Earnings

AMRH

SOLY

ULTA

45 Stocks Moving In Friday&#39;s Mid-Day Session

Serve Robotics Inc

Canaccord Genuity analyst Joseph Vafi maintains Blend Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) with a Buy and maintains $5.75 price target.

Price Target

Analyst Ratings

BLND

Canaccord Genuity Maintains Buy on Blend Labs, Maintains $5.75 Price Target

RSLS

Reshape Lifesciences Inc Files For Offering Of Up To 2.1M Shares Of Common Stock By Selling Stockholder

BiXin is a manufacturer of chillers, heat pumps, heat-recovery solutions and air-handling units. Focused on expanding the Vertiv chiller family, the acquisition strengthens Vertiv's portfolio of critical technologies and solutions in support of high-performance compute and AI applications globally.

Vertiv's Chinese Subsidiary Acquires Certain Assets And Technologies Of BiXin Energy Technology; No Terms Disclosed

EXTO

Almacenes Exito Plans To Delist American Depositary Shares From the New York Stock Exchange And Subsequent Arrangements, Company Says It Is Not Driven By Costs Or Concerns Regarding Compliance With The Requirements And Regulations

HC Wainwright &amp; Co. analyst Amit Dayal initiates coverage on AirJoule Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRJ#NASDAQ">AIRJ</a>) with a Buy rating and announces Price Target of $12.

Initiation

AIRJ

HC Wainwright & Co. Initiates Coverage On AirJoule Technologies with Buy Rating, Announces Price Target of $12

Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) with a Buy and lowers the price target from $30 to $20.

SONN

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $20

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Largo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGO#NASDAQ">LGO</a>) with a Buy and maintains $4.2 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Largo, Maintains $4.2 Price Target

On Thursday, December 19, U.S. markets closed mixed after initial gains faded. Stocks mainly remained flat as the Fed forecasted fewer 2025 rate cuts and higher inflation. Jobless claims fell, and Q3 GDP was revised to 3.1%, supporting the Fed&#8217;s view. The Dow ended its 10-session losing streak.
The U.S. economy grew 3.1% in Q3, revised from 2.8% while existing home sales rose 4.8% in November to 4.15 million. Initial jobless claims fell by 22,000 to 220,000 in early December, below estimates of 230,000.
Most S&amp;P 500 sectors ended lower, led by losses in materials, real estate, and energy. In contrast, utilities and financials outperformed, closing the session higher.
The Dow Jones Industrial Average was up 0.04% and closed at 42,342.24, the S&amp;P 500 closed lower by 0.09% at 5,867.08, and the Nasdaq Composite slipped 0.10% to finish at 19,372.77.
Asia Markets Today
<ul>
<li>On Friday, Japan&#8217;s Nikkei 225 declined 0.22% and ended the session at 38,723.50, led by losses in the Communication, Steel, and Transportation Equipment sectors shares.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 fell 1.24% and ended the day at 8,067.00, led by losses in the Consumer Discretionary, Financials and Gold sectors.</li>
<li>India&#8217;s Nifty 50 slid 1.35% to 23,627.45, and the Nifty 500 was down 1.82%, closing at 22,337.55. Losses in the Real Estate, Power, and Capital Goods sectors led to the declines.</li>
<li>China&#8217;s Shanghai Composite fell 0.06% to close at 3,368.07, and the Shenzhen CSI 300 declined 0.45%, finishing the day at 3,927.74.</li>
<li>Hong Kong&#8217;s Hang Seng was down 0.16% and closed the session at 19,720.70.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 index was down 1.35%.</li>
<li>Germany&#8217;s DAX slid 1.42%.</li>
<li>France&#8217;s CAC fell 1.30%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 1.09%.</li>
<li>European shares headed for their worst week in three months as Trump&#8217;s tariff threats on the EU rattled investors already concerned about U.S. rates. The STOXX 600 fell 1.1%, with major indices and sectors declining sharply, including banks and miners.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 2.69% at $68.67/bbl, and Brent was down 0.99% at $72.16/bbl.</li>
<li>Oil prices declined this week due to concerns about slowing demand growth in the coming years, particularly from China. The market was further pressured by a stronger dollar and ongoing revisions to demand forecasts by OPEC and its allies.</li>
<li>Natural Gas rose 1.95% to $3.654.</li>
<li>Gold was trading higher by 0.49% at $2,620.71, Silver was down 0.44% to $29.277 and rose 0.02% to $4.0780.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were down 0.58%, S&amp;P 500 futures fell 0.82% and Nasdaq 100 futures declined 1.18%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. dollar index was down 0.24% to 108.15, the USD/JPY fell 0.44% to 156.73, and the USD/AUD rose 0.12% to 1.6050.</li>
<li>The dollar neared a two-year high, set for its third weekly gain amid expectations of prolonged high U.S. rates. Global currencies weakened, with the yen and euro under pressure.</li>
</ul>
Image via Shutterstock

Asia

Emerging Markets

Futures

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

US Dollar Hits New Higher While Asia And Europe Markets Slide, Oil Drops On China Demand Fears - Global Markets Today While US Slept

Wedbush analyst Nick Setyan maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Outperform and raises the price target from $200 to $220.

Wedbush Maintains Outperform on Darden Restaurants, Raises Price Target to $220

Stephens &amp; Co. analyst Jim Salera maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Equal-Weight and raises the price target from $164 to $175.

Stephens & Co. Maintains Equal-Weight on Darden Restaurants, Raises Price Target to $175

Telsey Advisory Group analyst Cristina Fernandez downgrades Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Outperform to Market Perform and lowers the price target from $93 to $80.

Downgrades

Telsey Advisory Group Downgrades Nike to Market Perform, Lowers Price Target to $80

Fennec Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FENC#NASDAQ">FENC</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/FRX#TSX">FRX</a>), a specialty pharmaceutical company, today announced that Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, has received positive final draft guidance from National Institute for Health and Care Excellence (NICE) recommending PEDMARQSI for the prevention of cisplatin-induced hearing loss in patients (aged 1 month to 17 years) with localized, non-metastatic, solid tumors.
PEDMARQSI&nbsp;is the first and only approved therapy in the EU and&nbsp;U.K. for the prevention of ototoxicity, or hearing loss, induced by cisplatin chemotherapy in patients 1 month to &lt;18 years of age with localized, non-metastatic solid tumors. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine will commercialize&nbsp;PEDMARQSI&#xAE;&nbsp;in&nbsp;Europe,&nbsp;Australia, and New Zealand.
"Securing access to PEDMARQSI is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment," said&nbsp;Jeff Hackman, chief executive officer and director of Fennec Pharmaceuticals. "We congratulate Norgine on their collaboration with NICE to reach this important agreement that recognizes the value of ototoxicity intervention as part of the cancer treatment journey."
Under the terms of the <a href="https://investors.fennecpharma.com/news-releases/news-release-details/fennec-pharmaceuticals-and-norgine-enter-exclusive-licensing">previously announced</a> exclusive licensing agreement with Norgine, Fennec received approximately $43 million in an upfront payment and will receive up to approximately $230 million in additional commercial and regulatory milestone payments along with double-digit tiered royalties on net sales of PEDMARQSI starting in the mid-teens and growing to the mid-twenties.

Government

Regulations

FENC

TSX:FRX

Fennec's PEDMARQSI Gains National Institute for Health and Care Excellence Support, Offers Hope for Young Patients

Elon Musk-led SpaceX&nbsp;on Thursday secured a contract to conduct two additional&nbsp;private astronaut missions to the&nbsp;International Space Station (ISS). These missions will utilize the&nbsp;Falcon 9 rocket and Crew&nbsp;Dragon capsule.
What Happened: SpaceX's Falcon 9 will launch two spaceflight missions for&nbsp;Vast Space, a California-based company.
Vast Space is focused on&nbsp;developing a private space station&nbsp;named Haven-1, which could potentially launch into orbit next year using a Falcon 9 rocket.&nbsp;The company's CEO Max Haot&nbsp;highlighted the significance of these missions in strengthening their collaboration with NASA and other space agencies, according to an announcement by the company.
Haot further mentioned that these missions enhance Vast&#8217;s capabilities&nbsp;in human spaceflight operations and&nbsp;position the company as a strong contender to develop the next-generation ISS successor.
See Also: <a href="https://www.benzinga.com/24/12/42571318/return-of-astronauts-sunita-williams-and-butch-wilmore-from-iss-further-delayed-now-expected-no-earlier-than-late-march">Astronauts Sunita Williams, Butch Wilmore&#8217;s Return From ISS Further Delayed: Now Expected No Earlier Than Late March</a>
Vast is participating in NASA&#8217;s&nbsp;Commercial Low Earth Orbit Destination&nbsp;program with its Haven-2 design, which could be operational by 2028.
While&nbsp;NASA has not yet approved&nbsp;Vast&#8217;s planned missions, SpaceX expressed readiness to proceed once approval is granted. SpaceX President and COO Gwynne Shotwell expressed enthusiasm for working with Vast to expand space travel opportunities.
"I am excited to work with Vast as they build more opportunities and destinations for more people to travel amongst the stars."
Why It Matters: The partnership between SpaceX and Vast Space comes at a time when&nbsp;the Musk-led startup is making significant strides in space exploration.
Recently, SpaceX&#8217;s Starship was <a href="https://www.benzinga.com/general/space/24/11/42151383/elon-musks-spacex-secures-new-moon-mission-contract-after-starships-successful-6th-test-flight">selected by Lunar Outpost</a> to deliver its new moon rover, Eagle, to the lunar surface following a successful suborbital test flight. This highlights SpaceX&#8217;s growing role in lunar exploration.
SpaceX has also been selected to launch <a href="https://www.benzinga.com/general/space/24/11/42181019/spacex-falcon-heavy-to-launch-nasas-dragonfly-mission-to-saturns-largest-moon-in-2028">NASA&#8217;s Dragonfly mission</a> to Saturn&#8217;s largest moon, Titan, in 2028, further cementing its position as a key player in space exploration. This mission, priced at approximately $256.6 million, will utilize the Falcon Heavy rocket, showcasing SpaceX&#8217;s diverse capabilities in launching complex space missions.
However, it hasn't been all smooth sailing for NASA, on the other hand. The agency's plans for the&nbsp;<a href="https://www.benzinga.com/general/space/24/12/42376708/nasa-mission-to-land-humans-on-moon-delayed-artemis-3-now-slated-for-mid-2027">Artemis missions</a>&nbsp;have faced delays, with the Artemis 3 mission now slated for mid-2027.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42575664/tesla-reportedly-in-talks-with-austin">Tesla Reportedly In Talks With Austin To Bring Autonomous Vehicles To Texas Roads</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

SPACE

Tech

SpaceX To Launch 2 More Private Astronaut Missions To ISS

PTIX

Protagenic Therapeutics Inc Files For Offering Of Up To 5.84M Shares Of Common Stock By Selling Stockholders

<a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_6548" title="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_6548">https://ec.europa.eu/commission/presscorner/detail/en/ip_24_6548</a>

NVDA

European Commission On Thursday Announced It Approved The Proposed Acquisition Of Run:ai Labs By NVIDIA

Chardan Capital analyst Rudy Li initiates coverage on Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) with a Buy rating and announces Price Target of $20.

MNMD

Chardan Capital Initiates Coverage On Mind Medicine with Buy Rating, Announces Price Target of $20

<a href="https://www.gov.uk/government/news/cma-could-approve-synopsys-ansys-merger-if-competition-concerns-are-resolved" title="https://www.gov.uk/government/news/cma-could-approve-synopsys-ansys-merger-if-competition-concerns-are-resolved">https://www.gov.uk/government/news/cma-could-approve-synopsys-ansys-merger-if-competition-concerns-are-resolved</a>

ANSS

SNPS

UK's CMA Said Could Approve Synopsys / Ansys Merger If Competition Concerns Are Resolved

Eshallgo Inc ("Eshallgo" or the "Company") (NasdaqCM: EHGO), one of the leading Chinese office integrator, agent, and service provider, and the investment fund CS Asia Opportunities Master Fund (hereinafter referred to as "CS Fund") jointly announced a landmark equity investment. According to the securities purchase agreement between the two parties, CS Fund will become one of the shareholders of EHGO by injecting up to $20 million in equity investment in tranches, demonstrating CS Fund's confidence and high recognition in EHGO's future development prospects.
In this cooperation, CS Fund will purchase a total of up to 4,166,660 shares of EHGO at a price of $4.8 per share in tranches. This strategic move not only provides EHGO with strong financial support but also build momentum in its further business expansion.

EHGO

Eshallgo Announces Major Equity Financing, With Up To $20M To Facilitate Its Entry into Tencent's Business Ecosystem

Until the app's reinstatement, Bigo Live remains unavailable for download on iOS App Store, while its existing users who had previously downloaded the app may continue to use the current version. Apart from the suspension of app availability to new users on iOS App Store as announced in this release, JOYY maintains normal operations globally.
 &nbsp;
 &nbsp;

JOYY Responds To Recent Media Reports; Says Bigo Live Reinstated On Google Play Store, Currently Fully Engaged In Discussions With Apple For Reinstatement To iOS App Store

This not only demonstrates ESHALLGO's steadfast pace in business expansion, officially entering the Tencent business ecosystem, but also signifies that the company will embark on a new mode of cooperation in the fields of office integration services and cloud gaming, jointly exploring this market.

Eshallgo Reveals Acquisition Of D&K Asset Management (Hong Kong) Co., Ltd., And Establishment Of A Deep Strategic Partnership With Beijing Liuliuqiu Cultural Development Co

Serve Robotics prices $40M equity financing at $4 per share

Offerings

Small Cap

Press Releases

Serve Robotics Inc. Common Stock to Be Quoted on OTCQB Under Ticker Symbol "SBOT"

Serve Robotics Inc. Announces Pricing of $40 Million Public Offering and Uplisting to the Nasdaq Capital Market Under New Ticker "SERV"

SERV

TSX:MG

UBER

Stellar Biotechnologies, Inc. - Common Shares

Comments

Serve Robotics Inc

Serve Robotics Inc (SBOT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga